Validation of serum tumor biomarkers in predicting advanced cystic mucinous neoplasm of the pancreas

Table 2 Performance of five serum tumor makers in predicting advanced cystic mucinous neoplasms

	SE (95%CI)	SP (95%CI)	PPV (95%CI)	NPV (95%CI)	AC	AUC	P value
CA19-9 (%)	54.2 (42.1-65.8)	90.4 (83.2-94.5)	78 (63.6.7-88)	75.9 (67.7-82.6)	76.5	0.766
CEA (%)	25 (15.9-45.9)	92.17 (85.26-96.13)	66.67 (46-82.8)	66.3 (58.3-73.4)	66.31	0.651	0.04
CA125 (%)	17.3 (8.7-30.8)	98.8 (92.54-99.9)	90 (54.1-99.5)	65.5 (56.5-73.7)	67.4	0.583	0.004
CA724 (%)	16.3 (7.3-31.3)	95.9 (87.7-98.9)	70 (35.4-91.9)	66 (56.1-74.8)	66.4	0.618	0.03
CA242 (%)	31.25 (12.1-58.5)	93.3 (66-99.7)	83.3 (36.5-99.1)	56 (35.3-75)	61.3	0.758	0.81
CA199 ± any one of other STMs	62.5 (50.3-73.4)	83.5 (75.1-89.5)	70.3 (57.4-80.8)	78 (69.5-84.8)	75.4	0.715	0.32

P value: Comparison results of areas under curves for carbohydrate antigen 19-9 and other serum tumor makers in predicting advanced-cystic mucinous neoplasms. SE: Sensitivity; SP: Specificity; PPV: Positive predictive value; NPV: Negative predictive value. AC: Accuracy; AUC: Area under curve; CA: Carbohydrate antigen; STM: Serum tumor maker.